Medicare Rx Pricing Plans Could Lead To "Inappropriate" R&D - MedPAC
Executive Summary
Administered pricing for a Medicare drug benefit could result in "inappropriate patterns of investment" in pharmaceutical research and development, the Medicare Payment Advisory Commission's June 1 report to Congress states.